Motolimod (VTX-2337) is primarily used in the field of oncology as an immune response modifier. It functions as a Toll-like receptor 8 (TLR8) agonist, which helps to stimulate the immune system to recognize and attack cancer cells more effectively. This makes it a valuable component in cancer immunotherapy, particularly in enhancing the body's natural defenses against tumors. It has been investigated in clinical trials for its potential to improve the efficacy of other cancer treatments, such as chemotherapy and radiation therapy, by boosting the immune response. Additionally, it is being explored for its role in treating certain types of solid tumors and hematologic malignancies, offering hope for more effective and targeted cancer therapies.